Topics

F. Hoffmann-La Roche Ltd: Roche's Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

08:05 EDT 27 Sep 2019 | FinanzNachrichten

The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior system...

Original Article: F. Hoffmann-La Roche Ltd: Roche's Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

NEXT ARTICLE

More From BioPortfolio on "F. Hoffmann-La Roche Ltd: Roche's Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma"

Quick Search